secwatch.observer — SEC 8-K summary
======================================

Issuer:     Unicycive Therapeutics, Inc. (UNCY)
CIK:        0001766140
Form:       8-K
Filed at:   2026-03-30T23:59:59+00:00
Accession:  0001213900-26-035961
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Unicycive Therapeutics FY2025 net loss $26.6M ($1.67/sh); OLC PDUFA date June 29, 2026
--------------------------------------------------------------------------------

- Net loss attributable to common holders: $26.6M ($1.67/sh) vs $37.8M ($5.65/sh) in FY2024.
- Cash, equivalents, securities $54.9M as of March 30, 2026; runway into 2027.
- FDA accepted OLC NDA resubmission; PDUFA target action date June 29, 2026.
- R&D expenses $9.1M (down from $20.0M); G&A $20.4M (up from $12.1M) due to commercial prep.
- Commercial readiness for potential OLC launch in 3Q26 ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1766140/000121390026035961/0001213900-26-035961-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1766140/000121390026035961/ea0283942-8k_unicycive.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-035961

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer